1. Home
  2. NSP vs AUPH Comparison

NSP vs AUPH Comparison

Compare NSP & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Insperity Inc.

NSP

Insperity Inc.

HOLD

Current Price

$38.55

Market Cap

1.7B

ML Signal

HOLD

Logo Aurinia Pharmaceuticals Inc

AUPH

Aurinia Pharmaceuticals Inc

HOLD

Current Price

$15.78

Market Cap

1.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NSP
AUPH
Founded
1986
1993
Country
United States
Canada
Employees
N/A
N/A
Industry
Professional Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.6B
IPO Year
1997
1999

Fundamental Metrics

Financial Performance
Metric
NSP
AUPH
Price
$38.55
$15.78
Analyst Decision
Hold
Buy
Analyst Count
3
4
Target Price
$47.67
$17.25
AVG Volume (30 Days)
910.8K
1.6M
Earning Date
11-03-2025
11-04-2025
Dividend Yield
6.24%
N/A
EPS Growth
N/A
N/A
EPS
0.45
0.55
Revenue
$6,757,000,000.00
$265,808,000.00
Revenue This Year
$4.71
$21.22
Revenue Next Year
$6.40
$15.40
P/E Ratio
$85.99
$28.81
Revenue Growth
3.19
20.62
52 Week Low
$31.00
$6.55
52 Week High
$95.98
$16.48

Technical Indicators

Market Signals
Indicator
NSP
AUPH
Relative Strength Index (RSI) 57.67 59.93
Support Level $34.14 $15.15
Resistance Level $36.32 $16.03
Average True Range (ATR) 1.32 0.50
MACD 0.84 -0.13
Stochastic Oscillator 90.83 64.33

Price Performance

Historical Comparison
NSP
AUPH

About NSP Insperity Inc.

Insperity Inc is a company that provides a wide range of human resources and business solutions designed to help businesses improve their performance. Small and midsize enterprises are the company's primary target customers. Majority of the company's products are offered through the company's Workforce Optimization and Workforce Synchronization solutions, which comprise various human resource functions, such as payroll and employment administration, employee benefits and compensation, government compliance, performance management, training and development services, and human capital management. The company generates all of its revenue in the United States.

About AUPH Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.

Share on Social Networks: